On July 11, 2024 Dynamic Cell Therapies (DCT) reported an investment of $1M from the Myeloma Investment Fund (MIF), the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation (MMRF), to accelerate the development of novel CAR-T cell technologies for patients with multiple myeloma (Press release, Dynamic Cell Therapies, JUL 11, 2024, View Source [SID1234644796]). DCT is developing technology platforms that will allow CAR-T cells to attack unique and differentiated tumor targets that will allow for durable responses to treatment, and DCT’s proprietary CAR-T cells have demonstrated superiority to FDA-approved CAR-T cells in animal models. These technology platforms will improve the safety and efficacy of CAR-T cell therapies and have immediate application for patients with hematological cancers, including multiple myeloma. Supported by this recent investment, DCT is on track to advance a product into patients within the next two years.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Despite current successes in treating patients with CAR-T cells, many patients with multiple myeloma still relapse after therapy," said Fred Mermelstein, Ph.D., Chief Executive Officer of DCT. "The support of the MMRF & the Myeloma Investment Fund provides key expertise that will enable us to hasten the development of novel and best-in-class CAR-T cell therapies for patients with relapsed and refractory multiple myeloma."
"At the MMRF, we are deeply committed to advancing novel treatments intended to improve patient outcomes and get us closer to cures. We are energized by DCT’s cutting-edge cell therapy approach as a potentially transformative answer to patients with relapsed or refractory myeloma," said Michael Andreini, President and CEO of the Multiple Myeloma Research Foundation (MMRF).